An expert overview of pulmonary fibrosis in sarcoidosis

被引:10
作者
Gupta, Rohit [1 ]
Kim, Jin Sun [1 ]
Baughman, Robert P. [2 ]
机构
[1] Temple Univ Hosp & Med Sch, Thorac Med & Surg, Philadelphia, PA USA
[2] Univ Cincinnati, Dept Med, Cincinnati, OH 45221 USA
关键词
Sarcoidosis; pulmonary fibrosis; advanced pulmonary sarcoidosis; respiratory failure; lung transplantation; HIGH-RESOLUTION CT; LUNG TRANSPLANTATION; DOUBLE-BLIND; CLINICAL CHARACTERISTICS; INTERNATIONAL SOCIETY; INFLIXIMAB THERAPY; HYPERTENSION; DISEASE; DIAGNOSIS; METHOTREXATE;
D O I
10.1080/17476348.2023.2183193
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
IntroductionAdvanced pulmonary sarcoidosis refers to phenotypes of pulmonary sarcoidosis that often lead to significant loss of lung function, respiratory failure, or death. Around 20% of patients with sarcoidosis may progress to this state which is mainly driven by advanced pulmonary fibrosis. Advanced fibrosis often presents with associated complications of sarcoidosis including infections, bronchiectasis, and pulmonary hypertension.Areas coveredThis article will focus on the pathogenesis, natural history of disease, diagnosis, and potential treatment options of pulmonary fibrosis in sarcoidosis. In the expert opinion section, we will discuss the prognosis and management of patients with significant disease.Expert opinionWhile some patients with pulmonary sarcoidosis remain stable or improve with anti-inflammatory therapies, others develop pulmonary fibrosis and further complications. Although advanced pulmonary fibrosis is the leading cause of death in sarcoidosis, there are no evidence-based guidelines for the management of fibrotic sarcoidosis. Current recommendations are based on expert consensus and often include multidisciplinary discussions with experts in sarcoidosis, pulmonary hypertension, and lung transplantation to facilitate care for such complex patients. Current works evaluating treatments include the use of antifibrotic therapies for treatment in advanced pulmonary sarcoidosis.
引用
收藏
页码:119 / 130
页数:12
相关论文
共 158 条
  • [81] Transforming growth factor-β gene polymorphisms in sarcoidosis patients with and without fibrosis
    Kruit, Adijan
    Gmtters, Jan C.
    Ruven, Henk J. T.
    van Moorsel, Coline H. M.
    Weiskirchen, Rw
    Mengsteab, Senait
    van den Bosch, Jules M. M.
    [J]. CHEST, 2006, 129 (06) : 1584 - 1591
  • [82] Aspergillosis and sarcoidosis
    Lachkar, S.
    Dominique, S.
    Thiberville, L.
    Nouvet, G.
    Genevois, A.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : 943 - 953
  • [83] ELEVATED CONCENTRATIONS OF SOLUBLE INTERLEUKIN-2 RECEPTORS IN SERUM SAMPLES AND BRONCHOALVEOLAR LAVAGE FLUIDS IN ACTIVE SARCOIDOSIS
    LAWRENCE, EC
    BROUSSEAU, KP
    BERGER, MB
    KURMAN, CC
    MARCON, L
    NELSON, DL
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (04): : 759 - 764
  • [84] Le Pavec J., 2021, EUR RESPIR J, V58
  • [85] Lewis MM, 2002, SARCOIDOSIS VASC DIF, V19, P154
  • [86] PROLONGED USE OF METHOTREXATE FOR SARCOIDOSIS
    LOWER, EE
    BAUGHMAN, RP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (08) : 846 - 851
  • [87] SAFETY OF MACITENTAN IN SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION: A CASE-SERIES
    Mathijssen, H.
    Huitema, M. P.
    Bakker, A. L. M.
    Mager, J. J.
    Snijder, R. J.
    Grutters, J. C.
    Post, M. C.
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2020, 37 (01) : 74 - 78
  • [88] Maturu VN, 2016, SARCOIDOSIS VASC DIF, V33, P372
  • [89] McKinzie BP, 2010, AM J MED SCI, V339, P1, DOI 10.1097/MAJ.0b013e3181b97635
  • [90] Meholic AKL., 1996, FUNDAMENTALS CHEST R, P120